GILD
Gilead Sciences, Inc. · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +5.4% · net new positions 0.0% — formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 175 | +1 | 941.63M | $119.04B | +5 | −3 |
| Q1 2026 | 176 | +4 | 930.86M | $129.53B | +6 | −3 |
| Q4 2025 | 171 | 0 | 1.00B | $122.89B | +1 | — |
| Q3 2025 | 23 | -1 | 603.99M | $67.03B | — | −2 |
| Q2 2025 | 22 | -1 | 560.26M | $62.11B | — | −1 |
| Q1 2025 | 20 | 0 | 255.31M | $28.60B | — | — |
| Q4 2024 | 20 | +1 | 270.33M | $24.97B | +1 | — |
| Q3 2024 | 18 | 0 | 213.42M | $17.89B | — | — |
| Q2 2024 | 18 | — | 202.41M | $13.88B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 76.55M | +0.4% | $6.42B | 1.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 34.60M | +50.9% | $2.90B | 0.5% | ▲ Add | 2 | SEC ↗ ×9 |
| 3 | Dodge & Cox ✦ | 33.05M | -0.2% | $2.77B | 1.6% | ▼ Trim | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 27.54M | +2.1% | $2.30B | 0.2% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passive) | 17.70M | +1.8% | $1.48B | 0.2% | ▲ Add | 2 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 5.02M | +1702.5% | $420.70M | 0.4% | ▲ Add | 2 | SEC ↗ ×2 |
| 7 | Renaissance Technologies ✦ | 4.19M | -17.2% | $351.17M | 0.5% | ▼ Trim | 2 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 3.35M | +17.7% | $280.71M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 9 | Arrowstreet Capital ✦ | 3.00M | -34.6% | $251.24M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 10 | Point72 Asset Management ✦ | 2.31M | +350.1% | $193.27M | 0.7% | ▲ Add | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 1.94M | -5.4% | $162.64M | 0.2% | ▼ Trim | 2 | SEC ↗ ×4 |
| 12 | Millennium Management ✦ | 1.24M | -51.0% | $104.31M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 13 | Marshall Wace ✦ | 1.02M | +749.4% | $85.82M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 14 | D. E. Shaw & Co. ✦ | 741.20K | -77.8% | $62.14M | 0.1% | ▼ Trim | 2 | SEC ↗ ×2 |
| 15 | Two Sigma Investments ✦ | 698.67K | -79.0% | $58.58M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 16 | Gotham Asset Management ✦ | 255.17K | -9.3% | $21.39M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 17 | Bridgewater Associates ✦ | 206.94K | -73.8% | $17.35M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 8.95K | -32.2% | $750,431 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 61.30K shares, $8,543 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.60K sh · $229,907
Officer · 600 sh · $87,174
Officer · 800 sh · $115,566
Officer · 3.00K sh · $435,870
Officer, Director · 7.99K sh · $1.19M
Officer, Director · 1.60K sh · $236,014
Officer, Director · 5.41K sh · $807,856
Director · 3.40K sh · $504,296
Director · 3.12K sh · $462,432
Director · 4.60K sh · $684,590
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology